FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793996849> ?p ?o ?g. }

• W2793996849 endingPage "3058" @default.
• W2793996849 startingPage "3053" @default.
• W2793996849 abstract "Purpose: p95HER2 is a truncated form of HER2 that confers resistance to trastuzumab in vitro, but clinical results have been conflicting to date. Given that p95HER2 levels correlate with total HER2 expression levels, which confer better outcomes, we sought to evaluate the p95HER2/HER2 ratio in the North Central Cancer Treatment Group N0337 and N98-32-52 trials.Experimental Design: The HERmark assay and VeraTag technology (Monogram Biosciences) were used to measure total HER2 and p95HER2 expression levels in 91 patient samples.Results: In the multivariate model, increasing total HER2 level was significantly associated with longer (OS; HR, 0.33; P = 0.002) and decreasing p95HER2 level was significantly associated with longer OS (HR, 4.2; P = 0.01). Total HER2 expression level was significantly associated with longer progression-free survival (PFS) (HR, 0.57; P = 0.04), whereas p95HER2 level was not (HR, 1.7; P = 0.25). However, there was a positive association between p95HER2 and total HER2 expression levels (R2 = 0.48; P < 0.001). Consistent with our hypothesis, the ratio of p95HER2/HER2 was significantly associated with worsening PFS (HR, 1.7; P = 0.04) and OS (HR, 2.8; P = 0.002). Patients with the highest tertile of p95HER2/HER2 values had significantly less favorable PFS (HR, 1.8; P = 0.06) and OS (HR, 2.3; P = 0.02).Conclusions: A high p95HER2/HER2 ratio identified patients with metastatic breast cancer with poor outcomes on trastuzumab-based therapies. Further investigation of the p95HER2/HER2 ratio as a potential prognostic or predictive biomarker for HER2-targeted therapy is warranted. Clin Cancer Res; 24(13); 3053-8. ©2018 AACR." @default.
• W2793996849 created "2018-03-29" @default.
• W2793996849 creator A5006833753 @default.
• W2793996849 creator A5018432685 @default.
• W2793996849 creator A5023221128 @default.
• W2793996849 creator A5025775968 @default.
• W2793996849 creator A5026951319 @default.
• W2793996849 creator A5042931433 @default.
• W2793996849 creator A5043601605 @default.
• W2793996849 creator A5047379707 @default.
• W2793996849 creator A5052187738 @default.
• W2793996849 creator A5059982063 @default.
• W2793996849 creator A5065306642 @default.
• W2793996849 creator A5080124249 @default.
• W2793996849 creator A5081802864 @default.
• W2793996849 creator A5083535676 @default.
• W2793996849 creator A5086021121 @default.
• W2793996849 creator A5090009905 @default.
• W2793996849 date "2018-07-01" @default.
• W2793996849 modified "2023-10-17" @default.
• W2793996849 title "High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)" @default.
• W2793996849 cites W1974685860 @default.
• W2793996849 cites W2000269004 @default.
• W2793996849 cites W2004505325 @default.
• W2793996849 cites W2005446948 @default.
• W2793996849 cites W2012732226 @default.
• W2793996849 cites W2021019188 @default.
• W2793996849 cites W2023460670 @default.
• W2793996849 cites W2023681515 @default.
• W2793996849 cites W2023764867 @default.
• W2793996849 cites W2100794900 @default.
• W2793996849 cites W2104289405 @default.
• W2793996849 cites W2104728809 @default.
• W2793996849 cites W2104816881 @default.
• W2793996849 cites W2116424772 @default.
• W2793996849 cites W2123299533 @default.
• W2793996849 cites W2127433418 @default.
• W2793996849 cites W2137853125 @default.
• W2793996849 cites W2142329860 @default.
• W2793996849 cites W2144499620 @default.
• W2793996849 cites W2147761019 @default.
• W2793996849 cites W2167121370 @default.
• W2793996849 cites W2172265576 @default.
• W2793996849 doi "https://doi.org/10.1158/1078-0432.ccr-17-1864" @default.
• W2793996849 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6314664" @default.
• W2793996849 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29530935" @default.
• W2793996849 hasPublicationYear "2018" @default.
• W2793996849 type Work @default.
• W2793996849 sameAs 2793996849 @default.
• W2793996849 citedByCount "22" @default.
• W2793996849 countsByYear W27939968492019 @default.
• W2793996849 countsByYear W27939968492020 @default.
• W2793996849 countsByYear W27939968492021 @default.
• W2793996849 countsByYear W27939968492022 @default.
• W2793996849 countsByYear W27939968492023 @default.
• W2793996849 crossrefType "journal-article" @default.
• W2793996849 hasAuthorship W2793996849A5006833753 @default.
• W2793996849 hasAuthorship W2793996849A5018432685 @default.
• W2793996849 hasAuthorship W2793996849A5023221128 @default.
• W2793996849 hasAuthorship W2793996849A5025775968 @default.
• W2793996849 hasAuthorship W2793996849A5026951319 @default.
• W2793996849 hasAuthorship W2793996849A5042931433 @default.
• W2793996849 hasAuthorship W2793996849A5043601605 @default.
• W2793996849 hasAuthorship W2793996849A5047379707 @default.
• W2793996849 hasAuthorship W2793996849A5052187738 @default.
• W2793996849 hasAuthorship W2793996849A5059982063 @default.
• W2793996849 hasAuthorship W2793996849A5065306642 @default.
• W2793996849 hasAuthorship W2793996849A5080124249 @default.
• W2793996849 hasAuthorship W2793996849A5081802864 @default.
• W2793996849 hasAuthorship W2793996849A5083535676 @default.
• W2793996849 hasAuthorship W2793996849A5086021121 @default.
• W2793996849 hasAuthorship W2793996849A5090009905 @default.
• W2793996849 hasBestOaLocation W27939968491 @default.
• W2793996849 hasConcept C121608353 @default.
• W2793996849 hasConcept C126322002 @default.
• W2793996849 hasConcept C143998085 @default.
• W2793996849 hasConcept C2775930923 @default.
• W2793996849 hasConcept C2779786085 @default.
• W2793996849 hasConcept C530470458 @default.
• W2793996849 hasConcept C71924100 @default.
• W2793996849 hasConceptScore W2793996849C121608353 @default.
• W2793996849 hasConceptScore W2793996849C126322002 @default.
• W2793996849 hasConceptScore W2793996849C143998085 @default.
• W2793996849 hasConceptScore W2793996849C2775930923 @default.
• W2793996849 hasConceptScore W2793996849C2779786085 @default.
• W2793996849 hasConceptScore W2793996849C530470458 @default.
• W2793996849 hasConceptScore W2793996849C71924100 @default.
• W2793996849 hasFunder F4320337351 @default.
• W2793996849 hasIssue "13" @default.
• W2793996849 hasLocation W27939968491 @default.
• W2793996849 hasLocation W27939968492 @default.
• W2793996849 hasLocation W27939968493 @default.
• W2793996849 hasLocation W27939968494 @default.
• W2793996849 hasLocation W27939968495 @default.
• W2793996849 hasLocation W27939968496 @default.
• W2793996849 hasOpenAccess W2793996849 @default.
• W2793996849 hasPrimaryLocation W27939968491 @default.
• W2793996849 hasRelatedWork W1722328147 @default.

• next